Department of Cancer Biology and Pharmacology, University of Illinois College of Medicine at Peoria, Peoria, IL, USA; Department of Pharmacology, KVSR Siddhartha College of Pharmaceutical Sciences, Vijayawada, Andhra Pradesh, India.
Department of Cancer Biology and Pharmacology, University of Illinois College of Medicine at Peoria, Peoria, IL, USA.
Neurochem Int. 2022 Dec;161:105436. doi: 10.1016/j.neuint.2022.105436. Epub 2022 Oct 23.
Tissue-type plasminogen activator (t-PA) expression is known to increase following transient focal cerebral ischemia and reperfusion. Previously, we reported downregulation of t-PA upon suppression of matrix metalloproteinase-12 (MMP-12), following transient focal cerebral ischemia and reperfusion. We now present data on the temporal expression of t-PA in the brain after transient ischemia, as well as the interaction between MMP-12 and t-PA, two proteases associated with the breakdown of the blood-brain barrier (BBB) and ischemic brain damage. We hypothesized that there might be reciprocal interactions between MMP-12 and t-PA in the brain after ischemic stroke. This hypothesis was tested using shRNA-mediated gene silencing and computational modeling. Suppression of t-PA following transient ischemia and reperfusion in rats attenuated MMP-12 expression in the brain. The overall effect of t-PA shRNA administration was to attenuate the degradation of BBB tight junction protein claudin-5, diminish BBB disruption, and reduce neuroinflammation by decreasing the expression of the microglia/macrophage pro-inflammatory M1 phenotype (CD68, iNOS, IL-1β, and TNFα). Reduced BBB disruption and subsequent lack of infiltration of macrophages (the main source of MMP-12 in the ischemic brain) could account for the decrease in MMP-12 expression after t-PA suppression. Computational modeling of in silico protein-protein interactions indicated that MMP-12 and t-PA may interact physically. Overall, our findings demonstrate that MMP-12 and t-PA interact directly or indirectly at multiple levels in the brain following an ischemic stroke. The present findings could be useful in the development of new pharmacotherapies for the treatment of stroke.
组织型纤溶酶原激活物(t-PA)的表达已知在短暂性局灶性脑缺血再灌注后增加。此前,我们报道了基质金属蛋白酶-12(MMP-12)抑制后短暂性局灶性脑缺血再灌注时 t-PA 的下调。我们现在提供了短暂性脑缺血后大脑中 t-PA 表达的时间进程以及 MMP-12 和 t-PA 之间相互作用的相关数据,这两种蛋白酶与血脑屏障(BBB)的破坏和缺血性脑损伤有关。我们假设在缺血性中风后,MMP-12 和 t-PA 之间可能存在相互作用。该假设通过 shRNA 介导的基因沉默和计算模型进行了检验。在大鼠短暂性缺血再灌注后抑制 t-PA 可减轻大脑中 MMP-12 的表达。t-PA shRNA 给药的总体效果是减轻 BBB 紧密连接蛋白 Claudin-5 的降解,减少 BBB 破坏,并通过降低小胶质细胞/巨噬细胞促炎 M1 表型(CD68、iNOS、IL-1β和 TNFα)的表达来减少神经炎症。BBB 破坏减少和随后巨噬细胞(缺血性大脑中 MMP-12 的主要来源)浸润减少可能是 t-PA 抑制后 MMP-12 表达减少的原因。计算蛋白质-蛋白质相互作用的模拟表明,MMP-12 和 t-PA 可能在缺血性中风后在大脑的多个水平上直接或间接相互作用。总体而言,我们的发现表明,MMP-12 和 t-PA 在缺血性中风后在大脑中直接或间接相互作用于多个水平。这些发现可能有助于开发治疗中风的新药物疗法。